CorMedix Therapeutics Announces Share Repurchase Program
Rhea-AI Summary
CorMedix Therapeutics (Nasdaq: CRMD) announced a Board‑authorized share repurchase program to buy up to $75 million of common stock through December 31, 2027. The company expects repurchases could begin as early as Q1 2026 and had approximately $150 million cash and 79.3 million shares outstanding as of Dec 31, 2025.
Repurchases may occur via negotiated transactions, block trades, open market purchases or trading plans and are subject to market conditions, liquidity, cash flow and applicable securities laws. The program is discretionary and may be suspended or discontinued.
Positive
- Board authorized up to $75 million in share repurchases
- Repurchases may begin in Q1 2026, providing timeline clarity
- $150 million cash balance as of Dec 31, 2025 supports buyback capacity
Negative
- Repurchases could consume up to 50% of cash on hand as of Dec 31, 2025
- Buybacks are subject to market conditions, liquidity and cash flow constraints
Market Reaction
Following this news, CRMD has gained 6.83%, reflecting a notable positive market reaction. Our momentum scanner has triggered 13 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $8.29. This price movement has added approximately $42M to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
CRMD was down 3.24% while close peers were mixed: ABUS +0.73%, MRVI -0.59%, QURE -3.36%, UPB +1.44%, VERV -0.09%. Momentum scanner only flagged SPRY at about +4%, supporting a stock-specific narrative for this buyback announcement.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 29 | Analyst Day announcement | Neutral | +3.5% | Announced in‑person and virtual Analyst Day with portfolio and pipeline updates. |
| Jan 09 | Conference presentation | Neutral | +1.6% | Disclosed CEO presentation at J.P. Morgan Healthcare Conference with webcast access. |
| Jan 08 | Leadership changes | Positive | -32.8% | CEO became Chairman, governance changes and commentary on positive cashflow and pipeline. |
| Jan 08 | Preliminary earnings | Neutral | -32.8% | Preliminary Q4/FY 2025 results and FY 2026 guidance with program and reimbursement updates. |
| Dec 18 | Clinical data update | Positive | +4.1% | Real‑world DefenCath data showing large reductions in infections and hospitalizations. |
Recent news shows positive clinical and event updates often coinciding with gains, while the January 8 leadership and earnings cluster saw a sharp selloff despite strong headline metrics.
Over the last few months, CorMedix reported strong preliminary Q4/FY 2025 financials, including substantial net revenue and adjusted EBITDA, alongside guidance for FY 2026. However, those updates and leadership/board changes on Jan 8, 2026 coincided with a steep -32.77% reaction. By contrast, positive real‑world DefenCath data on Dec 18, 2025 and later announcements about conferences and an Analyst Day on Feb 10, 2026 saw modest gains. Today’s buyback fits a pattern of management emphasizing cash generation and shareholder returns after becoming a multi‑product, cash‑flow‑positive company.
Regulatory & Risk Context
An effective S-3ASR filed on Oct 7, 2025 registers up to 6,323,833 existing-shareholder shares for resale, including tranches for Deerfield funds. The company will receive no proceeds from these sales, though it lists about $140,000 of related legal fees and expenses.
Market Pulse Summary
The stock is up +6.8% following this news. A strong positive reaction aligns with management’s decision to authorize up to $75 million of share repurchases through 2027, supported by $150 million in cash and a recent track record of substantial revenue and EBITDA. Historically, clearly positive clinical and commercial updates, such as the DefenCath real‑world data, coincided with gains. Investors would also have weighed the existing S-3ASR for 6,323,833 resale shares, which can influence supply dynamics over time.
Key Terms
block trades financial
open market purchases financial
trading plans financial
AI-generated analysis. Not financial advice.
BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced its Board of Directors has approved a share repurchase program, which authorizes the Company to repurchase up to
“With a strong balance sheet, solid operating performance, and expected ongoing cash flow generation, we believe we are well positioned to execute this share repurchase program while continuing to advance our growth strategy,” said Joseph Todisco, Chairman & CEO of CorMedix Therapeutics. “The program provides a disciplined way to return value to shareholders while preserving the financial flexibility to invest in our business, including potential inorganic opportunities. We remain confident in our long-term outlook and in the potential of our late-stage clinical programs to deliver meaningful benefits for patients.”
CorMedix expects to begin repurchasing shares as early as Q1 2026 and had approximately
Repurchases may be made at management’s discretion from time to time in privately negotiated transactions, through block trades, pursuant to open market purchases or pursuant to trading plans as permitted under applicable securities laws. In addition, any repurchases under the authorization will be subject to prevailing market conditions, liquidity and cash flow considerations, applicable securities laws and regulations, and other factors. The share repurchase program does not require CorMedix Therapeutics to acquire any amount of shares, and may be suspended or discontinued at any time.
About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN® (minocycline) for Injection, REZZAYO® (rezafungin for injection), VABOMERE® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA® (delafloxacin), and KIMYRSA® (oritavancin), as well as TOPROL-XL® (metoprolol succinate).
CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: www.cormedix.com or www.melinta.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements including, but not limited to statements regarding financial and operating results, cash flow, shareholder return, outlook of the business, expectations regarding timing, execution and impact of the share repurchase program, expectations and timing regarding clinical studies and development and expectations of CorMedix’s product pipeline, expectations regarding implementation and perceived benefits of CorMedix’s products. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its most recent Annual Report on Form 10-K, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
What does the CorMedix (CRMD) $75 million repurchase program authorize?
When will CorMedix (CRMD) start repurchasing shares under the program?
How large is CorMedix’s (CRMD) cash position relative to the buyback?
Will CorMedix (CRMD) have to buy the full $75 million in shares?
How might CorMedix (CRMD) execute repurchases under the program?
